I normally keep that to myself because personally

I normally keep that to myself because personally I don’t like to complain or sounds negative. If I was being honest I’d say NASH and BTD will be a hit but the past has proven otherwise so it’s wise to tamper my expectations.

Also as for as the SP you may very well be right as I stated the float is so large I don’t expect crazy movement with BTD alone for an extended period of time. However, I will say this. Our little company isn’t a one trick show, so I’m assuming the investors and market will take BTD and NASH as a major win or stepping stone forward for this company. A partnership even better.

With all the bio stocks I’ve played around with over the years I’ve never seen one with so much potential. I think many investors are on the sidelines basically saying this company is too good to be true. Show me the data!

So I guess we will have to wait and see.

Daniel Rizzo
Federal Whistleblower / Special Operations Tactical Unit
USAF: Phoenix Raven #2143
HHS & SEC Whistleblower: HL-1412396
DOJ Investigation Report/ Whistleblower ID: 20250705-0001
NIH Case Reference: CS1137565


Founder & CEO of FireGate Bioscience
USPTO: Lead Inventor of the HIV Cure & AI Federal Oversight Program

⸻

Public Links
FireGate Bioscience: https://www.firegatebioscience.com
NotYourDrug.com: https://www.notyourdrug.com